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PURPOSE. Asymmetry in disease progression between left and right eyes can occur in Stargardt
disease (STGD1), and this needs to be considered in novel therapeutic trials with a fellow-eye
paired controlled design. This study investigated the inter-eye discordance of best-corrected
visual acuity (BCVA) and progression of RPE atrophy in STGD1.
METHODS. We performed a retrospective cohort study collecting 68 STGD1 patients (136 eyes)
with ‡1 ABCA4 variants and ‡0.5-year follow-up on BCVA and fundus autofluorescence. We
compared inter-eye correlations of RPE atrophy progression between early-onset (10 years),
intermediate-onset (11–44), and late-onset (‡45) STGD1 and ABCA4 variant combinations by
v2 tests. We identified associations of discordant baseline BCVA and RPE atrophy with
discordant RPE atrophy progression by odds ratios (OR). We defined discordance by
differences >1.5 interquartile ranges 6 first/third interquartiles.
RESULTS. Progression of RPE atrophy correlated moderately between eyes (q ¼ 0.766), which
decreased with later onset (P ¼ 9.8 3 107) and lower pathogenicity of ABCA4 combinations
(P ¼ 0.007). Twelve patients (17.6%) had discordant inter-eye RPE atrophy progression,
associated with baseline discordance of RPE atrophy (OR, 6.50 [1.35–31.34]), but not BCVA
(OR, 0.33 [0.04–2.85]).
CONCLUSIONS. Lower inter-eye correlations are more likely found in late-onset STGD1 and
patients carrying low pathogenic ABCA4 combinations. To achieve the highest power in a
therapeutic trial, early-phase studies should minimize inter-eye discordance by selecting early-
onset STGD1 patients carrying severe ABCA4 variants without evidence of asymmetry at
baseline.
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Stargardt disease (STGD1) is one of the most common retinaldystrophies. Loss of macular function causes bilateral loss of
visual acuity, usually at childhood.1,2 The first manifestations of
the disease may also occur in older patients, up to the seventh
decade.3,4 In general, the severity of the disease is associated
with the age of onset; young patients tend to do worse.5 The
variation in age of onset and rate of progression is, for the most
part, the result of combinations of over 900 variants in the
ABCA4 gene.6
ABCA4 encodes the adenosine triphosphate-binding cas-
sette, subfamily A, member 4 transporter protein, which actively
removes all-trans-retinal with its conjugate N-retinylidene-
phosphatidylethanolamine from the photoreceptor outer seg-
ment disks.7 Impaired removal results in condensation reac-
tions, which lead to toxic levels of bisretinoids in the outer
segment disks. Through phagocytosis of these outer segments,
bisretinoids accumulate as lipofuscin deposits in the RPE. These
lipofuscin deposits are observed as yellowish-white flecks in the
posterior pole.8 The accumulation of toxic lipofuscin eventually
leads to atrophy of the RPE and photoreceptors with subsequent
loss of the neurosensory retina and choriocapillaris.9
Over time, RPE atrophy progresses, as uni- or multifocal
areas enlarge and coalesce. However, there is considerable
variability in these patterns of atrophy; they range from large
central atrophic areas in early-onset STGD1 patients that can be
seen at adolescence2 to relatively small atrophic lesions
encircling the fovea in older patients with late-onset STGD1.3
The difference in atrophic lesion not only varies between
patients,10 but also the patterns of RPE loss may differ
significantly between eyes of one patient. Even though the
extent of abnormalities is often similar between left and right
eyes,11,12 some cases with remarkable differences have been
described.13
Profound inter-eye differences in disease progression have
impact on the statistical power in clinical trials; treated and
untreated eyes must demonstrate a larger difference than do
the inter-eye differences by their natural course. Otherwise, the
required sample size will be unreasonably large. However, in
early-phase clinical trials for novel treatments of STGD114–16
and other retinal dystrophies, small therapeutic effects have to
be evaluated, generally within 2 years, with no more than a few
dozen patients. Thus, better knowledge of inter-eye correla-
tions is needed for fellow-eye paired controlled trials in which
the untreated eyes of participants serve as a control.
In view of these upcoming interventional trials, we have
studied the extent of asymmetric inter-eye progression of RPE
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atrophy in patients with STGD1. Fundus autofluorescence
(FAF) imaging is a valuable tool to evaluate progression of RPE
atrophy over time.17–20 We therefore analyzed inter-eye
discordance of RPE atrophy progression using FAF imaging
along with visual acuity. We hypothesized that a later disease
onset and less pathogenic combinations of ABCA4 variants
contribute to asymmetric inter-eye progression and that the
asymmetry will increase when asymmetry at baseline is already
present.
METHODS
Patient Selection
We selected patients from the STGD1 database, containing 454
cases, of the Department of Ophthalmology at Radboud
University Medical Center (Nijmegen, The Netherlands). We
included patients in whom the clinical diagnosis of STGD1 was
supported by the presence of ‡1 (likely) pathogenic ABCA4
variants with a follow-up data of ‡6 months on FAF imaging.
Ninety-three STGD1 patients met these inclusion criteria.
Ten cases were excluded because no RPE atrophy had
developed during the entire follow-up time. Nine cases
displayed RPE atrophy to such a degree that the lesions
extended beyond the limits of the FAF image. One case was
excluded because choroidal neovascularization occurred in
one eye. Five cases were excluded because they participated in
an interventional trial.21 The remaining 68 cases were included
in this study. The patient inclusion process is shown in
Supplementary Figure S1. This retrospective cohort study was
approved by the Institutional Ethics Committee and was
performed in accordance with the Declaration of Helsinki.
Measurements
We documented sex, age at onset, age at baseline, and follow-
up time. Age at onset was defined as either the age at which
visual complaints were first noted, or if unavailable, the age
when the diagnosis was made. Disease-onset groups were
based on previously reported cut-off points: early-onset
STGD1, 10 years,2 and late-onset STGD1, ‡45 years.3 The
remaining patients were grouped as intermediate-onset
STGD1, 11 to 44 years. The age at baseline was the first visit
with available imaging and visual acuity tests.
Best-corrected visual acuity (BCVA) was measured with a
Snellen or Early Treatment Diabetic Retinopathy Study chart,
then transformed into the logarithm of the minimum angle of
resolution (logMAR) for analysis. Fundus autofluorescence (k¼
488 nm, emission 500–700 nm) imaging was performed using a
confocal scanning laser ophthalmoscope (Spectralis HRA-
OCT; Heidelberg Engineering, Heidelberg, Germany). The field
of view was set at 308 3 308 or 558 3 558 and was centered on
the macula.22
Image Quantification
The total RPE atrophy area was automatically quantified in FAF
images by an observer-independent image analysis algorithm.
The algorithm automatically segmented the area starting from
an arbitrarily selected seed point inside the atrophic area. This
method was based on a combination of a region-growing
algorithm and a dynamic, user-independent threshold selection
procedure using Otsu thresholding. Areas were square root
(=) transformed to correct for baseline RPE atrophy area.23 A
good agreement has previously been observed between
manual area measurements and the automatically quantified
values (Sanchez CI, et al. IOVS 2015;56:ARVO E-Abstract 5258)
and was found to be consistent with the agreement within this
cohort (intra-class correlation coefficient, 0.977; 95% confi-
dence interval [CI], 0.951–0.987).
Genetic Analysis
All reported ABCA4 variants (Supplementary Table S1) were
classified as follows: (1) pathogenic: truncating alleles,
significantly enriched in ABCA4-LOVD (http://www.LOVD.nl/
ABCA4, in the public domain), which contains 6903 variants
(861 unique variants) reported in 3987 persons with STGD1 or
autosomal recessive cone-rod dystrophy (Cornelis SS, Cremers
FPM, unpublished data, 2016); (2) likely pathogenic: non-
truncating alleles, significantly enriched in ABCA4-LOVD; (3)
likely benign: allele frequency (AF) ABCA4-LOVD/AF ExAC
non-Finnish Caucasian <1; (4) benign: ExAC AF >0.006; (5)
unknown pathogenicity: AF ABCA4-LOVD/AF ExAC non-
Finnish Caucasian >1, however not significantly enriched.
Patients were then grouped by combinations of ABCA4
pathogenicity: (1) pathogenic/pathogenic; (2) pathogenic/
likely pathogenic; (3) likely pathogenic/likely pathogenic; (4)
pathogenic in combination with unknown pathogenicity,
(likely) benign, or a variant that was not published until
December 31, 2015; (5) likely pathogenic in combination with
unknown pathogenicity or (likely) benign (Cornelis SS,
Cremers FPM, unpublished data, 2016).
Statistical Analysis
We analyzed BCVA and RPE atrophy measurements using
analysis software (SPSS version 22; IBM Corp., IBM SPSS
Statistics, Chicago, IL, USA) with parametric tests. Retinal
pigment epithelium atrophy progression rates were calculated
by the difference at the baseline and last follow-up visit divided
by the follow-up time. Differences in disease duration and
follow-up time between disease-onset groups were analyzed
with the Kruskal-Wallis test.
We used Pearson’s correlation coefficients (q) to assess
inter-eye correlations of baseline BCVA, baseline RPE atrophy,
and RPE atrophy progression. We compared these correlations
between disease-onset groups and ABCA4 variant combination
groups by first performing a Fisher transformation:
z 0 ¼ 1
2
ln
1 þ q
1  q : ð1Þ
Then, these z0 scores were compared for homogeneity. The
test for homogeneity employs the v2 distribution for two and
four degrees of freedom:
v2 ¼
X
ðni  3Þðz 0i 2Þ 
X
ðni  3Þðz 0iÞ
 2
X
ðni  3Þ
ð2Þ
where the summation is over the three disease-onset groups
and five ABCA4 variant combination groups, respectively.24
Baseline BCVA and RPE atrophy differences between
measurements and the average measurements of both eyes
were calculated and plotted according to the method of Bland
and Altman to assess the intra-individual agreement graphical-
ly.25 Limits of agreement between eyes were plotted for each
disease-onset group.
Lin’s concordance correlation coefficient qc was calculated
to evaluate the extent of inter-eye symmetry of baseline BCVA,
baseline RPE atrophy, and RPE atrophy progression.26–28 The
qc consists of the product of a precision coefficient (Pearson’s
q) and an accuracy coefficient va. The accuracy coefficient va
indicates how far the best-fit line of all paired left- and right-eye
measurements deviates from the 458 line on a square scatter
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plot and is defined as 2-þ1=-þv2, where scale shift -¼ rOD/rOS
and location shift relative to the scale is v ¼ lODlOSﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃrODrOSp (OD, right
eye; OS, left eye).29 If all paired measurements exactly lie on
the 458 line, a coefficient of 1 would be found, indicating
perfect symmetry. Strength-of-agreement criteria were as
follows: almost perfect, >0.90; substantial, 0.80–0.90; moder-
ate, 0.65–0.80; poor, <0.65.30
As standard deviations can be affected by extreme
differences and rely on distributional assumptions, box and
whisker plots were used to identify outliers by differences
>1.5 interquartile ranges (IQR) below the first (Q1) or above
the third (Q3) interquartiles in baseline BCVA, baseline RPE
atrophy, and RPE atrophy progression. Odds ratios were
calculated to identify associations of discordant BCVA and
RPE atrophy at baseline with RPE atrophy progression.
We performed sample-size calculations and a sensitivity
analysis for a theoretical intervention using nQuery Advisor 7.0
(Statistical Solutions, Boston, MA, USA). We used a two-sided
paired t-test for differences in means of RPE atrophy
progression with a test significance level (a) of 0.05 and a
power of (1  b) of 0.80. Standard deviations of differences
between RPE atrophy progression of treated and nontreated
eyes were obtained from the standard deviations and
correlations of left and right eyes using the formula rd ¼
=(r12 þ r22  2qr1r2).
RESULTS
Patient Characteristics
A total of 68 patients (136 eyes) were included in this study (26
men and 42 women). The median age at onset was 8.5 (range,
4–10), 20 (range, 11–42), and 50 (range, 45–69) years for 14
early-onset STGD1, 33 intermediate-onset STGD1, and 21 late-
onset STGD1 patients, respectively. At baseline, the median
disease duration was 5 years (range, 0–39). The distribution did
not differ between the three disease-onset categories. Details of
patient characteristics and inter-eye correlations at baseline
and follow-up are depicted in Table 1.
Baseline Inter-Eye Correlations of Best-Corrected
Visual Acuity. At baseline, the mean (6 standard deviation)
BCVA in the right and left eyes was 0.66 (60.51) logMAR and
0.72 (60.53) logMAR, respectively. Twenty-four right eyes and
23 left eyes were identified as the better-seeing eye; 21 pairs of
eyes had equal BCVA. The overall inter-eye correlation (q) in
BCVA at baseline was 0.756 and did not differ between disease-
onset groups, although a trend of decreasing correlations at
later disease-onset was also observed at follow-up.
Next, we compared the average and differences of baseline
BCVA between the left and right eyes by a Bland-Altman plot
(Supplementary Fig. S2A), revealing discordance up to 1.70
logMAR. This discordance was most pronounced in 13 patients
(two early-onset STGD1, seven intermediate-onset STGD1, and
four late-onset STGD1), as defined by outlying differences
below Q11.53 IQR or above Q3þ1.53 IQR (Supplementary
Fig. S2B). Overall, this resulted in an inter-eye agreement (qc) in
baseline BCVA of 0.751 (95% confidence interval (CI), 0.626–
0.838).
Baseline Inter-Eye Correlations of RPE Atrophy. At
baseline, the mean = RPE atrophy area in the right and left
eyes was 1.56 mm (61.36) and 1.45 mm (61.36), respectively.
Twenty-nine right eyes and 34 left eyes had the smallest RPE
atrophy area; 5 pairs of eyes had no RPE atrophy. Although
baseline RPE atrophy between the left and right eyes was
highly correlated (q¼ 0.878), the correlation was significantly
decreased in late-onset STGD1 patients.
TABLE 1. Characteristics and Inter-Eye correlations at Baseline and at Follow-up in 68 Stargardt Patients
Patient Characteristics Early-Onset STGD1 Intermediate-Onset STGD1 Late-Onset STGD1 P Value
Sex 7 male 9 male 10 male
7 female 24 female 11 female
Age at onset, y (median and range) 8.5 (4–10) 20 (11–42) 50 (45–69)
Baseline
Disease duration, y (median and range) 7 (0–27) 4 (0–39) 5 (0–26) 0.768*
Age, y (median and range) 14.5 (9–31) 36 (13–56) 59 (45–81)
BCVA, logMAR (mean and SD) 0.419†
OD 1.08 (60.41) 0.67 (0.50) 0.36 (60.39)
OS 1.09 (60.28) 0.77 (0.49) 0.40 (60.55)
Correlation, q 0.830 0.723 0.619
= RPE atrophy, mm (mean and SD) 5.5 3 108†
OD 1.79 (61.29) 1.31 (61.52) 1.79 (61.10)
OS 1.76 (61.27) 1.28 (61.58) 1.51 (61.03)
Correlation, q 0.992 0.931 0.601
Follow-up
Follow-up time, y (median and range) 5.7 (1.1–9.7) 3.1 (0.9–9.5) 3.8 (0.5–7.6) 0.220*
Age, y (median and range) 21 (11–36) 33 (15–59) 64 (47–86)
BCVA, logMAR (mean and SD) 0.0497†
OD 1.23 (60.29) 0.93 (60.44) 0.63 (60.60)
OS 1.23 (60.29) 0.88 (60.52) 0.54 (60.60)
Correlation, q 0.897 0.767 0.527
= RPE atrophy, mm (mean and SD) 6.1 3 104†
OD 2.73 (61.23) 1.89 (61.69) 2.29 (61.55)
OS 2.77 (61.26) 1.86 (61.62) 2.17 (61.49)
Correlation, q 0.974 0.938 0.670
Median and ranges are shown for time variables. Mean and standard deviations (SD) are shown for BCVA and = RPE atrophy.
* Kruskal-Wallis test for differences in disease duration and follow-up.
† v2 With two degrees of freedom for differences in inter-eye correlations.
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The Bland-Altman plot (Supplementary Fig. S3A) showed
inter-eye differences up to 2.49 mm of baseline = RPE atrophy
area. An inter-eye difference below Q11.53 IQR or above Q3
þ 1.53 IQR (Supplementary Fig. S3B), that is, discordant RPE
atrophy at baseline, was identified in eight patients (interme-
diate-onset STGD1, four patients; late-onset STGD1, four
patients). The overall inter-eye agreement (qc) of baseline
RPE atrophy was 0.876 (95% CI, 0.806–0.921).
Discordance of RPE Atrophy Progression Rates
Inter-Eye Correlations of RPE Atrophy Progression.
The median follow-up time was 3.9 years (range, 0.5–9.7), of
which the distribution did not differ between all disease-onset
categories. The mean = RPE atrophy progression rates in the
right and left eyes were 0.21 (60.20) mm/y and 0.20 (60.21)
mm/y, respectively. Thirty-five right eyes and 31 left eyes were
identified as the eye with the slowest progression rate. Two
pairs of eyes showed no progression in 3.0 and 3.4 years,
respectively. The progression rates of = RPE atrophy
correlated between the left and right eyes with q ¼ 0.766
and increased with earlier disease-onset groups (P ¼ 9.8 3
107). Evaluating the inter-eye agreement in progression of RPE
atrophy, the agreement between the eyes was qc¼ 0.765 (95%
CI, 0.645–0.847) (Fig. 1).
Discordant Progression Rates of RPE Atrophy. Twelve
out of 68 patients (early-onset STGD1, two patients [14%];
intermediate-onset STGD1, four patients [12%]; late-onset
STGD1, six patients [29%]) had discordant RPE atrophy
progression rates between their eyes by differences below Q1
 1.53 IQR or above Q3þ 1.53 IQR. In four of these patients,
the eye with the largest RPE atrophy area progressed faster
than the other eye, thus increasing inter-eye discordance of
RPE atrophy over time (mean difference, 0.26 [60.10] mm/y;
Fig. 2A). In the other eight patients, the eye with the smallest
RPE atrophy area progressed faster than the other eye,
therefore reducing inter-eye discordance of RPE atrophy (mean
difference, 0.30 [60.12] mm/y; Fig. 2B). The remaining 56
FIGURE 1. A square scatter plot of inter-eye = RPE progression.
Circles are patients with differences in baseline = RPE atrophy
between their eyes within Q1,3 6 1.5 3 IQR. Triangles are patients
who fall outside the Q1,3 6 1.53 IQR for differences in baseline= RPE
atrophy. Dashed line: 458 line of perfect agreement. Q1, first
interquartile; Q3, third interquartile; IQR, interquartile range.
FIGURE 2. Concordant and discordant inter-eye progression in Stargardt disease. (A) 60-year old female with a disease duration of 1 year and
increasing inter-eye differences. ABCA4 variants: c.5461-10T>C:p.[Thr1821Valfs*13,Thr1821Aspfs*6]/c.2757A>C:p.(Glu919Asp). (B) Eighty-one-
year old female with a disease duration of 26 years and decreasing inter-eye differences. ABCA4 variants: c.5196þ1G>T:p.(?)/þ. (C) Twenty-six-year
old female with a disease durat ion of 6 years and simi la r progress ion rates between eyes. ABCA4 var iants :
c.1853G>A;4297G>A:p.(Gly618Glu;Val1433Ile)/c.2588G>C:p.[Gly863Ala;Gly863del].
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patients had similar progression rates between their eyes
(mean difference, 0.05 [60.04] mm/y, within Q1,36 1.53 IQR;
Fig. 2C).
Baseline RPE Atrophy and Genetic Associations With
Discordant RPE Atrophy Progression. Discordant RPE
atrophy at baseline was associated with discordant RPE
atrophy progression (odds ratio, 6.50; 95% CI, 1.35–31.34);
this association was not found for discordant BCVA at baseline
(odds ratio, 0.33; 95% CI, 0.04–2.85).
Furthermore, decreasing pathogenicity of ABCA4 variant
combinations were significantly associated with increasing
discordant inter-eye progression (P ¼ 0.007). Proportions and
correlations are depicted in Table 2.
Power Calculations of a Theoretical Intervention
Trial
The power of a paired-control intervention trial will depend on
the strength of correlations between pairs, that is, the left and
right eye of each patient, and the expected treatment effect.
For each two-fold increase in expected treatment effect,
approximately a four-fold decrease in patient numbers is
needed for a study at equal power. Stronger inter-eye
correlations will have a linear beneficial effect on the number
needed to include. The impact on these numbers is highest
when a relatively modest treatment effect is expected. For
instance, a correlation of q¼ 0.766 would require 44 patients,
whereas this number is reduced to 20 in the case of a
correlation of q ¼ 0.9 (Fig. 3). The specific inclusion criteria,
for example, disease onset, ABCA4 variant combinations, and
baseline discordance can significantly affect the number
needed to include.
DISCUSSION
Based on longitudinal FAF data in our current study, the overall
agreement of inter-eye RPE atrophy progression in STGD1 was
only moderate; it was highest in early-onset STGD1 and lowest
in late-onset STGD1. Discordant progression rates were found
in 12 out of 68 (17.6%) patients, which is surprisingly high
given that STGD1 is assumed to be a symmetrical inherited
retinal disease. Discordant progression rates resulted in eyes
either converging or diverging in atrophy size. Discrepancies of
RPE atrophy progression rates were associated with discrep-
ancies of RPE atrophy at baseline and less pathogenic ABCA4
variant combinations.
Autosomal retinal dystrophies are expected to be symmet-
rical owing to the similar genetic and environmental back-
ground of both eyes. The majority of STGD1 patients exhibit
bilateral symmetry in retinal features. Chen et al.12 illustrated
this symmetry in left and right eyes of 24 STGD1 patients; they
had highly correlated areas of RPE atrophy (Pearson’s q ¼
TABLE 2. Proportions of Combinations of ABCA4 Variants and Discordant RPE Atrophy Progression
ABCA4 Variant Combination
RPE Atrophy Progression
No Discordance Discordant Inter-Eye Correlation (Pearson’s q)
1. Pathogenic/pathogenic 3 1 0.995
2. Pathogenic/likely pathogenic 21 4 0.790
3. Likely pathogenic/likely pathogenic 9 0 0.597
4. Pathogenic/* 12 3 0.079
5. Likely pathogenic/* 11 4 0.346
* The second ABCA4 variant was likely benign, of unknown pathogenicity, or not found.
FIGURE 3. A sensitivity analysis for the power calculation of a theoretical intervention trial. Assuming a 30% reduction in disease progression
(treatment effect), 44 patients are needed (inter-eye correlation q¼ 0.766; b¼ 0.20, a¼ 0.05, two-sided paired samples t-test). The sample size will
decrease to 20 in the case of an inter-eye correlation of 0.9. In the case of a correlation in disease progression of 1, 0.8, 0.6, 0.4, 0.2, and 0 between
left and right eyes, 3, 38, 73, 108, 143, or 178 patients are needed, respectively.
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0.998). McBain et al.11 studied the atrophy progression rates in
12 STGD1 patients, reporting a strong inter-eye correlation
(Spearman’s q ¼ 0.846). In our cohort, these inter-eye
correlations of RPE atrophy were substantially lower, but they
can be explained by inclusion of late-onset STGD1 patients,
which decreased the overall correlation. Inter-eye correlations
of late-onset STGD1 were previously estimated to be moderate
(q ¼ 0.52).20 When late-onset STGD1 patients are excluded,
our inter-eye correlations were similar to those reported by
others.
Previous studies were limited by standard analyses of
correlations, which cannot address the absolute symmetry
within a patient. In contrast, we used Lin’s concordance
correlation coefficients and descriptive Bland-Altman plots,
which are more appropriate and previously described in age-
related macular degeneration.27 In addition, there is an
inherent increase in variability of inter-eye differences when
the magnitude of atrophic areas increases. We corrected this by
expressing the inter-eye differences as the square root, thus the
differences were proportional to the magnitude of measure-
ments. Moreover, square root transformation corrected base-
line dependence, which was reported previously with an
average atrophy enlargement increase of 0.016 mm2/y for each
month of follow-up.10
Although we found that progression rates for atrophy are
more likely to be discordant in eyes that differ more at
baseline, progression rates are rather unpredictable between
patients and between eyes within a patient. McBain et al.11
suggested that electroretinography could predict the rate of
atrophy progression, but they did not account for baseline
atrophy size. It would be interesting if discordance in
electroretinography between eyes of a patient would also
predict inter-eye differences in progression, independent of
their baseline atrophy size.10 Burke et al.31 indicated that
changes on optical coherence tomography would precede RPE
atrophy and may thus predict the rates of atrophy progression.
These potential predictors for disease progression need to be
addressed in future work.
The lower inter-eye correlations in older patients could be
explained by the increased time within which stochastic
factors, for example, small initial differences leading to
significant differences later, can influence phenotypic expres-
sion. Differences in ABCA4 variant expression may alter
disease severity between eyes with mild variants, which can
have a slightly different pathogenicity. In contrast, differences
in expression would not influence progression speed much in
severe ABCA4 combinations as both variants would cause an
equally severe phenotype.
The statistical power of a randomized controlled trial
increases when differences are measured between correlated
left and right eyes. To this extent, we recommend a fellow-eye
paired trial design for retinal dystrophies, for example, as
applied in a phase II gene therapy trial for choroideremia with
30 patients enrolled (ClinicalTrials.gov, NCT02407678). To
achieve 80% statistical power in this trial, an effect size of at
least 0.53 is required.32 For the same expected effect size, a
patient-controlled trial would need 58 patients in each arm.33
Even in multicenter trials, such high sample sizes are difficult
to obtain in rare retinal dystrophies. However, it is important to
bear in mind that a fellow-eye paired control is impossible for
pharmaceutical strategies in which both eyes of a patient are
being treated (ClinicalTrials.gov, NCT02402660). Furthermore,
it is preferred that an effect on relatively slow retinal
degeneration is detected to identify a potential long-term
benefit rather than a temporary gain of visual function.34
A therapeutic trial will gain a major advantage from a fellow-
eye control in early-onset STGD1 because of their high inter-
eye correlations. However, discordance was also present in
some of these younger patients. As the progression can be
better predicted in similar rather than in discordant eyes,
retinal asymmetry needs to be considered as an exclusion
criterion for small early-phase trials. Such stringent criteria will
increase the chance of detecting efficacy with fewer patients.
Criteria would include early-onset STGD1 patients with
concordant retinal abnormalities between their eyes carrying
severe ABCA4 variants; not only do these patients have the
highest inter-eye symmetry in disease progression, but they are
also expected to have the most severe disease course.1,2 In
these patients, therapy will potentially provide the most
benefit, and in these patients, its effect has the highest chance
to be detected.
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